Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2018 3
2019 3
2020 1
2021 3
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Granulocyte colony-stimulating factor in traumatic spinal cord injury.
Aschauer-Wallner S, Leis S, Bogdahn U, Johannesen S, Couillard-Despres S, Aigner L. Aschauer-Wallner S, et al. Among authors: johannesen s. Drug Discov Today. 2021 Jul;26(7):1642-1655. doi: 10.1016/j.drudis.2021.03.014. Epub 2021 Mar 27. Drug Discov Today. 2021. PMID: 33781952 Free article. Review.
In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis.
Schuster J, Dreyhaupt J, Mönkemöller K, Dupuis L, Dieterlé S, Weishaupt JH, Kassubek J, Petri S, Meyer T, Grosskreutz J, Schrank B, Boentert M, Emmer A, Hermann A, Zeller D, Prudlo J, Winkler AS, Grehl T, Heneka MT, Johannesen S, Göricke B, Witzel S, Dorst J, Ludolph AC; RAS-ALS Study Group. Schuster J, et al. Among authors: johannesen s. Eur J Neurol. 2024 Apr;31(4):e16204. doi: 10.1111/ene.16204. Epub 2024 Jan 19. Eur J Neurol. 2024. PMID: 38240416 Clinical Trial.
Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients.
Johannesen S, Budeus B, Peters S, Iberl S, Meyer AL, Kammermaier T, Wirkert E, Bruun TH, Samara VC, Schulte-Mattler W, Herr W, Schneider A, Grassinger J, Bogdahn U. Johannesen S, et al. Front Neurol. 2018 Nov 26;9:971. doi: 10.3389/fneur.2018.00971. eCollection 2018. Front Neurol. 2018. PMID: 30534107 Free PMC article.
Prognostic factors in ALS: a comparison between Germany and China.
Dorst J, Chen L, Rosenbohm A, Dreyhaupt J, Hübers A, Schuster J, Weishaupt JH, Kassubek J, Gess B, Meyer T, Weyen U, Hermann A, Winkler J, Grehl T, Hagenacker T, Lingor P, Koch JC, Sperfeld A, Petri S, Großkreutz J, Metelmann M, Wolf J, Winkler AS, Klopstock T, Boentert M, Johannesen S, Storch A, Schrank B, Zeller D, Liu XL, Tang L, Fan DS, Ludolph AC. Dorst J, et al. Among authors: johannesen s. J Neurol. 2019 Jun;266(6):1516-1525. doi: 10.1007/s00415-019-09290-4. Epub 2019 Mar 28. J Neurol. 2019. PMID: 30923935
Reconditioning the Neurogenic Niche of Adult Non-human Primates by Antisense Oligonucleotide-Mediated Attenuation of TGFβ Signaling.
Peters S, Kuespert S, Wirkert E, Heydn R, Jurek B, Johannesen S, Hsam O, Korte S, Ludwig FT, Mecklenburg L, Mrowetz H, Altendorfer B, Poupardin R, Petri S, Thal DR, Hermann A, Weishaupt JH, Weis J, Aksoylu IS, Lewandowski SA, Aigner L, Bruun TH, Bogdahn U. Peters S, et al. Among authors: johannesen s. Neurotherapeutics. 2021 Jul;18(3):1963-1979. doi: 10.1007/s13311-021-01045-2. Epub 2021 Apr 15. Neurotherapeutics. 2021. PMID: 33860461 Free PMC article.
Modeling and Bioinformatics Identify Responders to G-CSF in Patients With Amyotrophic Lateral Sclerosis.
Johannesen S, Huie JR, Budeus B, Peters S, Wirth AM, Iberl S, Kammermaier T, Kobor I, Wirkert E, Küspert S, Tahedl M, Grassinger J, Pukrop T, Schneider A, Aigner L, Schulte-Mattler W, Schuierer G, Koch W, Bruun TH, Ferguson AR, Bogdahn U. Johannesen S, et al. Front Neurol. 2021 Mar 18;12:616289. doi: 10.3389/fneur.2021.616289. eCollection 2021. Front Neurol. 2021. PMID: 33815246 Free PMC article.
Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders.
Peters S, Wirkert E, Kuespert S, Heydn R, Johannesen S, Friedrich A, Mailänder S, Korte S, Mecklenburg L, Aigner L, Bruun TH, Bogdahn U. Peters S, et al. Among authors: johannesen s. Pharmaceutics. 2022 Jan 15;14(1):200. doi: 10.3390/pharmaceutics14010200. Pharmaceutics. 2022. PMID: 35057094 Free PMC article.
14 results